ARS Pharmaceuticals shares surge 11.23% premarket after China approval for Neffy and Roth reiterates buy rating.

ARS Pharmaceuticals surged 11.23% in premarket trading following its announcement of China National Medical Products Administration (NMPA) approval for Neffy 2 mg, its epinephrine nasal spray for allergic reactions. This regulatory milestone, first reported 12–13 days prior, marked Neffy as the first community-use intranasal epinephrine product in China, expanding its commercial potential. Analysts at Roth and Simply Wall St. had previously highlighted the approval as a catalyst, reinforcing optimism about the drug’s market access and revenue prospects. While older news in September detailed FDA rejections in the U.S., recent positive developments in China and ongoing real-world data presentations overshadowed prior setbacks, driving the premarket rally.